XML 94 R78.htm IDEA: XBRL DOCUMENT v3.6.0.2
Related Party Transactions (Details) - USD ($)
1 Months Ended 12 Months Ended
Sep. 28, 2016
May 26, 2016
Mar. 16, 2016
Oct. 07, 2013
Mar. 24, 2010
Jan. 31, 2016
May 31, 2015
Mar. 31, 2012
Sep. 30, 2011
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
May 31, 2016
May 31, 2014
Related-Party Transactions (Textual) [Abstract]                            
Long-term other assets                   $ 2,113,147 $ 670,833      
Ownership percentage by parent                           85.00%
Payment of receivable                         $ 2,000,000  
Future payments to be received             $ 1,000,000              
Ownership             16.80%              
Payment of cash distribution                   1,000,000 1,000,000      
Investment in affiliated entity - PLS                   3,777,510 5,045,915      
Minority shareholders                            
Related-Party Transactions (Textual) [Abstract]                            
Payment of cash distribution                   $ 149,559 149,559      
Plumbline Life Sciences                            
Related-Party Transactions (Textual) [Abstract]                            
Carrying value of investment                           $ 0
Available-for-sale Securities                            
Related-Party Transactions (Textual) [Abstract]                            
Number of shares owned                         395,758  
Available-for-sale Securities | Plumbline Life Sciences                            
Related-Party Transactions (Textual) [Abstract]                            
Number of shares owned                   395,758        
VGX Pharmaceuticals | Available-for-sale Securities                            
Related-Party Transactions (Textual) [Abstract]                            
Number of shares owned             465,364              
First warrant | Fair Value, Inputs, Level 3                            
Related-Party Transactions (Textual) [Abstract]                            
Common stock purchase warrant (shares) 50,000               50,000          
Exercise price of a five-year warrant ($ per share) $ 24.00               $ 24.00          
Second warrant | Fair Value, Inputs, Level 3                            
Related-Party Transactions (Textual) [Abstract]                            
Common stock purchase warrant (shares)               150,000            
Exercise price of a five-year warrant ($ per share)               $ 20.00            
GeneOne (affiliated entity)                            
Related-Party Transactions (Textual) [Abstract]                            
Ownership target   35.00%       35.00%                
Term       20 years                    
Payment received for license granted         $ 3,000,000                  
Deferred revenue from affiliated entity         $ 3,000,000                  
Period over which deferred revenue from affiliated entity will be recognized in years         8 years                  
Accounts payable/accrued liability                   $ 379,000 165,000      
NIAID                            
Related-Party Transactions (Textual) [Abstract]                            
Revenue from related parties                   1,200,000 450,000 $ 479,000    
Operating expenses related to affiliated entity                   2,800,000 6,900,000 $ 4,200,000    
Accounts receivable from related parties                   441,000 4,000      
Long-term other assets                   $ 571,000 $ 373,000      
OncoSec | Second warrant                            
Related-Party Transactions (Textual) [Abstract]                            
Common stock purchase warrant (shares)                   150,000        
Exercise price of a five-year warrant ($ per share)                   $ 20.00        
Director                            
Related-Party Transactions (Textual) [Abstract]                            
Term     5 years                      
Revenue from related parties                   $ 341,000        
Operating expenses related to affiliated entity                   985,000        
Expenses to reimburse     $ 3,100,000                      
Accounts receivable                   152,000        
Due to related parties                   $ 671,000